Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 3
1971 5
1972 1
1975 2
1978 1
1979 1
1982 1
1985 3
1986 2
1987 1
1988 2
1990 4
1991 1
1992 4
1993 1
1995 1
1996 1
1997 2
1998 3
1999 3
2000 2
2001 3
2002 5
2003 7
2004 5
2005 9
2006 12
2007 23
2008 11
2009 25
2010 13
2011 11
2012 13
2013 20
2014 21
2015 16
2016 13
2017 11
2018 14
2019 9
2020 11
2021 14
2022 16
2023 12
2024 19
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

326 results

Results by year

Filters applied: . Clear all
Page 1
Ranibizumab for neovascular age-related macular degeneration.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Rosenfeld PJ, et al. Among authors: kaiser pk. N Engl J Med. 2006 Oct 5;355(14):1419-31. doi: 10.1056/NEJMoa054481. N Engl J Med. 2006. PMID: 17021318 Free article. Clinical Trial.
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Heier JS, et al. Among authors: kaiser pk. Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Ophthalmology. 2012. PMID: 23084240 Clinical Trial.
Review of gene therapies for age-related macular degeneration.
Khanani AM, Thomas MJ, Aziz AA, Weng CY, Danzig CJ, Yiu G, Kiss S, Waheed NK, Kaiser PK. Khanani AM, et al. Among authors: kaiser pk. Eye (Lond). 2022 Feb;36(2):303-311. doi: 10.1038/s41433-021-01842-1. Epub 2022 Jan 11. Eye (Lond). 2022. PMID: 35017696 Free PMC article. Review.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Among authors: kaiser pk. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metzig C, Holz FG. Heier JS, et al. Among authors: kaiser pk. Ophthalmology. 2016 Nov;123(11):2376-2385. doi: 10.1016/j.ophtha.2016.07.032. Epub 2016 Sep 17. Ophthalmology. 2016. PMID: 27651226 Clinical Trial.
Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials.
Danzig CJ, Khanani AM, Kaiser PK, Chang MA, Kovach JL, Lally DR, Rachitskaya A, Sheth VS, Vajzovic L, Clark J, Tang J, Zhu L, Desai D, Chakravarthy U. Danzig CJ, et al. Among authors: kaiser pk. Ophthalmol Retina. 2024 Nov;8(11):1052-1060. doi: 10.1016/j.oret.2024.04.023. Epub 2024 May 7. Ophthalmol Retina. 2024. PMID: 38719191 Free article. Clinical Trial.
EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results From the Phase 3 Mylight Study.
Bordon AF, Kaiser PK, Wolf A, Cen L, Heyn J, Urosevic D, Dodeller F, Allmannsberger L, Silva R. Bordon AF, et al. Among authors: kaiser pk. Retina. 2024 Oct 1;44(10):1704-1713. doi: 10.1097/IAE.0000000000004174. Epub 2024 Sep 12. Retina. 2024. PMID: 39287533 Free PMC article. Clinical Trial.
Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular Degeneration.
Bala S, Barbosa GCS, Mohan N, Srivastava SK, Kaiser PK, Sastry A, Babiuch AS, Sears J, Talcott KE, Yuan A, Rachitskaya A, Ehlers JP, Schachat AP, Lin P, Sharma S, Mammo DA. Bala S, et al. Among authors: kaiser pk. Ophthalmol Retina. 2025 Aug;9(8):756-766. doi: 10.1016/j.oret.2025.02.002. Epub 2025 Feb 7. Ophthalmol Retina. 2025. PMID: 39923899 Free article.
Wound construction.
Trichonas G, Kaiser PK. Trichonas G, et al. Among authors: kaiser pk. Dev Ophthalmol. 2014;54:71-6. doi: 10.1159/000360451. Epub 2014 Aug 26. Dev Ophthalmol. 2014. PMID: 25196754 Review.
326 results